Very few people avoid chickenpox in countries where the disease is common. This is because more than 8 out of 10 people susceptible to chickenpox will become infected after exposure to the virus. It is very rare for a person to get chickenpox more than once.
After recovery from chickenpox, the virus stays dormant (inactive) in the nerves near the spine. Years later the virus can become active again and cause herpes zoster, commonly known as shingles. Shingles usually affects adults 50 years of age or older and people of any age with a weakened immune system (see herpes zoster).
How you get it
The virus can spread from person to person through droplets in the air from coughing, sneezing or laughing. It can also be transferred by direct contact with the fluid that is in the chickenpox or shingles rash blisters.
A person with chickenpox can pass the virus on for 1-2 days before they get the rash until after the rash blisters have dried up, which usually takes 5-7 days.
The early symptoms of chickenpox may include a mild fever, loss of appetite, headache and feeling tired, followed by the appearance of a red rash that becomes blistered and itchy, mostly on the trunk, head and face with some on the arms and legs. The blisters can occur in the eyes, mouth and throat, vagina and urinary tract. For up to 5-7 days, new blisters appear, filled with liquid containing the virus which then form crusts that fall off after 1-2 weeks.
Chickenpox is usually mild in children, with most healthy children recovering fully. However for some it can be more severe requiring hospitalisation, and in rare cases, death. Complications can include skin infections, inflammation of the brain, pneumonia and blood infections. Chickenpox tends to be more severe in adolescents and adults, pregnant women and their unborn babies and people of any age with poorly functioning immune systems.
Those who catch the disease from another household member often have more severe chickenpox than the person they caught it from.
For healthy children the main treatment measures include reducing pain, discomfort and itching associated with the blisters, preventing dehydration and skin infection, and as necessary providing early antibiotics if skin infection does occur.
For healthy adolescents and adults, the use of antiviral medicine, such as acyclovir, should be considered in addition to comfort measures. Antiviral medicine started within 24 hours of the rash appearing may reduce the severity of the disease. (See ‘After exposure’ below.
Tips for managing chickenpox symptoms:
- Drink plenty of fluids
- Trim nails short and consider using mittens or clean socks, to decrease the risk of scratching, especially overnight
- A cool or lukewarm bath every 3-4 hours. Do not use soap. Try adding oatmeal, baking soda or non-irritating moisturising bath lotion to the bath water. Pat dry, do not rub, after bathing
- Moisturise with non-irritating skin lotion. Calamine lotion is not recommended as it can dry out the skin.
- Dress in loose fitting clothing and change the bed linen daily
- If blisters in the mouth and throat affect drinking and eating, take clear cool drinks and soft bland foods and avoid acidic drinks such as fruit juices
- Use paracetamol if needed to relieve discomfort and pain
- If itching is severe, ask your doctor about antihistamine medicine in liquid or tablet form
Aspirin or any medicine with an ingredient name including the words ‘salicylate’ or ‘salicylic acid’ MUST NOT be given to children with chickenpox because of the risk of Reye’s Syndrome.
Changes in skin colour after the blister crusts fall off may last for months. Permanent scarring may also occur.
Around one in every 20 healthy children with chickenpox will develop a bacterial skin infection, usually from scratching, that needs to be treated with antibiotics. If untreated, bacterial skin infections can lead to bacterial infection in other parts of the body, including the blood (septicaemia). This can be serious and lead to death.
Although rare, chickenpox infection can cause inflammation in other parts of the body, such as the central nervous system, joints (arthritis), bones, lungs (pneumonia), liver (hepatitis), blood vessels supplying the brain with blood and brain.
Pneumonia is more likely to occur as a complication in adults, particularly women in the last trimester of pregnancy.
Maternal chickenpox during pregnancy can infect the fetus. The highest risk period is during the first 20 weeks of pregnancy. Up to two in 100 infants exposed to chickenpox before birth will be born with congenital varicella syndrome and may have skin scarring, eye, limb and brain abnormalities, developmental delay and a poor outcome. Maternal chickenpox, within five days before and two days after delivery, can infect the newborn infant. Up to 30 in 100 newborns with chickenpox develop severe disease that can result in death.
Prior to exposure
Chickenpox vaccine is delivered to children on the immunisation schedule at 15 months of age. Vaccination is recommended for non-immune adolescents and adults, and non-immune woman prior to pregnancy. People with a weakened immune system are at high risk, but may not be able to have the vaccination themselves, so close contacts of these people are recommended to be vaccinated. The vaccine is funded for certain high-risk individuals and/ or their close contacts.
- Varicella vaccine can be given, if necessary, after exposure to the disease to people over nine months of age. Studies have shown that giving the vaccine to children 12 years or younger within 72 - 96 hours of exposure to chickenpox can prevent the disease developing or reduce the severity of the disease. In older age groups, vaccination upon exposure may be less effective. Receiving the vaccine after exposure to the disease will not make the disease more severe at any age.
- Varicella-zoster (zoster) immunoglobulin (ZIG), a human blood product, should be given to certain high-risk people as soon as possible after, and within 96 hours of, exposure to the virus::
- pregnant, non-immune women*
- newborn infants whose mother had onset of chickenpox within seven days before or after delivery
- hospitalised premature infants whose mothers have no history of chickenpox, or who were born before 28 weeks’ of pregnancy or with a birth weight less than 1000 grams, irrespective of maternal history
- children and adults with weakened immune systems and no reliable history of chickenpox
*Pregnant women with no reliable history of chickenpox should have an urgent blood test to check for immunity after exposure to chickenpox. If the blood test suggests no immunity against chickenpox, they can receive ZIG within 96 hours of exposure, or wait for the onset of symptoms and begin antiviral medicine immediately.
Complications of disease
Responses to vaccine
As with any medicine, very rarely, severe allergic reactions occur following immunisation
- Centers for Disease Control and Prevention. Prevention of varicella recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-04):1-40.
- Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, et al. Safety of varicella vaccine after licensure in the United States: Experience from reports to the Vaccine Adverse Event Reporting System, 1995–2005. J Infect Dis. 2008;197(Suppl 2):S170-7.
- Civen R, Chaves SS, Jumaan A, Wu H, Mascola L, Gargiullo P, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28(11):954-9.
- Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728-43.
- Gershon A, Marin M, Seward J. Varicella vaccines. In: Plotkin S, Orenstein W, Offit P, Edwards K, editors. Plotkin’s Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 1145-80.
- Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): Five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine. 2010;28(36):5878-82.
- Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365-76. Tarlow MJ, Walters S. Chickenpox in childhood: A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. 1998;36(Suppl 1):39-47.
- Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis. 1994;170(3):522-6.
- Macartney K, Heywood A, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.Cochrane Database Syst Rev. 2014;(6):Art. No.: CD001833.
- Ministry of Health. Immunisation handbook 2017 2nd Edition [Internet]. Wellington: Ministry of Health; 2018 [cited 2020 July 20]. Available from: https://www.health.govt.nz/publication/immunisation-handbook-2017
- Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine. 2005;23(10):1205-8.
- Pace D. Review of varicella zoster virus: From epidemiology to prevention. Malta Medical Journal. 2008;20(3):7-11.
- WHO Strategic Advisory Group of Experts on Immunisation (SAGE) Working Group on Varicella and Herpes Zoster Vaccines. Systematic review of available evidence on effectiveness and duration of protection of varicella vaccines [Internet]. Geneva: World Health Organization; 2014 [cited 2020 July 20]. Available from: http://www.who.int/immunization/sage/meetings/2014/april/presentations_background_docs/en/